td-8236
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2018 (NCT03652038)
Timeline
Indications
Studied for
Mechanism of action
- Tyrosine-protein kinase JAK3INHIBITOR
JAK3 inhibitor
- Tyrosine-protein kinase JAK2INHIBITOR
JAK2 inhibitor
- Jak1 proteinINHIBITOR
JAK1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04150341 | Phase 2 | Nov 30, 2019 | Theravance |
| NCT03652038 | Phase 1 | Oct 1, 2018 | Theravance |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theravance | For profit | 2 | 2 | 2 | 2018 |
1 organizations
Page 1 / 1